Drug Patents Expiring in 2032
1. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(9 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
2. List of Abraxane drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393318 | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
| US9597409 | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Mar, 2032
(8 years from now) | |
|
US9393318 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
|
US9597409 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer
Dosage: POWDER;INTRAVENOUS
3. List of Acetadote drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(8 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: INJECTABLE;INTRAVENOUS
4. List of Adzenys Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
| US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
| US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 15 September, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
5. List of Adzenys Xr-odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265737 | NEOS THERAPS | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
| US9017731 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
| US8709491 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
6. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(8 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
33
United States
18
Hong Kong
18
Japan
17
European Union
16
Israel
15
China
14
EA
13
Korea, Republic of
12
Spain
12
Poland
12
Denmark
10
South Africa
9
Hungary
6
Canada
4
Cyprus
4
New Zealand
4
Slovenia
4
Australia
3
San Marino
3
RS
3
Portugal
3
Croatia
3
Mexico
2
Brazil
1
Turkey
1
Chile
1
Ukraine
1
Peru
1
United Kingdom
7. List of Akynzeo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11312698 | HELSINN HLTHCARE | Fosnetupitant chloride hydrochloride having improved stability |
May, 2032
(8 years from now) | |
| US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(8 years from now) | |
| US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(8 years from now) | |
| US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 19, 2023 |
NCE-1 date: 2022-04-19
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
AKYNZEO family patents
11
United States
6
China
3
Japan
2
Lithuania
2
Hungary
1
New Zealand
1
Cyprus
1
San Marino
1
Ecuador
1
RS
1
Uruguay
1
Georgia
1
Portugal
1
Canada
1
Brazil
1
India
1
Dominican Republic
1
Spain
1
Malaysia
1
Croatia
1
Jordan
1
ME
1
Hong Kong
1
EA
1
Korea, Republic of
1
Ukraine
1
Guatemala
1
Chile
1
Israel
1
Costa Rica
1
Peru
1
Slovenia
1
Tunisia
1
Argentina
1
Morocco
1
Australia
1
Philippines
1
Mexico
1
Moldova, Republic of
1
Nicaragua
1
Taiwan
1
South Africa
1
Poland
1
Colombia
1
Singapore
1
Denmark
1
European Union
8. List of Alecensa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
9. List of Aliqopa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS
ALIQOPA family patents
3
United States
3
European Union
2
Japan
2
Taiwan
1
New Zealand
1
Cyprus
1
San Marino
1
Ecuador
1
RS
1
Uruguay
1
China
1
Portugal
1
Canada
1
Brazil
1
Dominican Republic
1
Spain
1
Malaysia
1
Croatia
1
Jordan
1
EA
1
Hong Kong
1
ME
1
Korea, Republic of
1
Chile
1
Guatemala
1
Ukraine
1
Israel
1
Costa Rica
1
Peru
1
Slovenia
1
Tunisia
1
Argentina
1
Denmark
1
Cuba
1
Australia
1
Mexico
1
South Africa
1
Poland
1
Colombia
1
Singapore
1
AP
1
Morocco
10. List of Alkindi Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717740 | ETON | Treatment of adrenal insufficiency |
Nov, 2032
(9 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
11. List of Amvuttra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) | |
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
| Orphan Drug Exclusivity (ODE) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: 2026-06-13
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
AMVUTTRA family patents
16
United States
7
Japan
6
Korea, Republic of
6
European Union
5
China
4
Israel
4
Australia
3
Chile
3
Hong Kong
3
Mexico
3
Singapore
2
New Zealand
2
Canada
2
India
2
Spain
2
Croatia
2
Lithuania
2
Slovenia
2
Argentina
2
Russia
2
Denmark
1
Ecuador
1
RS
1
Portugal
1
Brazil
1
Dominican Republic
1
Malaysia
1
EA
1
Guatemala
1
Ukraine
1
Costa Rica
1
Hungary
1
Peru
1
Tunisia
1
Philippines
1
Nicaragua
1
Poland
1
Colombia
12. List of Aptiom drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(9 years from now) | |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures
Dosage: TABLET;ORAL
13. List of Aristada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(8 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(9 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
14. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(8 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
33
United States
18
Hong Kong
18
Japan
17
European Union
16
Israel
15
China
14
EA
13
Korea, Republic of
12
Spain
12
Poland
12
Denmark
10
South Africa
9
Hungary
6
Canada
4
Cyprus
4
New Zealand
4
Slovenia
4
Australia
3
San Marino
3
RS
3
Portugal
3
Croatia
3
Mexico
2
Brazil
1
Turkey
1
Chile
1
Ukraine
1
Peru
1
United Kingdom
15. List of Avycaz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
| New Patient Population (NPP) | Dec 20, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
16. List of Azstarys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079928 | COMMAVE THERAP | Methylphenidate-oxoacid conjugates, processes of making and using the same |
Jul, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 7, 2026 |
NCE-1 date: 2025-05-07
Market Authorisation Date: 07 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
AZSTARYS family patents
7
United States
5
Korea, Republic of
5
Israel
4
Japan
3
Canada
3
Mexico
2
China
2
Spain
2
European Union
1
New Zealand
1
RS
1
Portugal
1
Brazil
1
Malaysia
1
Croatia
1
Chile
1
Lithuania
1
Ukraine
1
Hungary
1
Slovenia
1
Argentina
1
Australia
1
Poland
1
South Africa
1
Russia
1
Colombia
1
Singapore
1
Denmark
17. List of Belbuca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(9 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM;BUCCAL
18. List of Bijuva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11110099 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10675288 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10639375 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
| US8993549 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8633178 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11166963 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8933059 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11103513 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9006222 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11033626 | THERAPEUTICSMD INC | Progesterone formulations having a desirable pk profile |
Nov, 2032
(9 years from now) | |
| US9301920 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9114145 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US9114146 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8846648 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8846649 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10206932 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US11103516 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8993548 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US8987237 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
| US10052386 | THERAPEUTICSMD INC | Progesterone formulations |
Nov, 2032
(9 years from now) | |
| US10806740 | THERAPEUTICSMD INC | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
19. List of Bijuva drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529360 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(9 years from now) | |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 October, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
20. List of Biktarvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
| New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
| M (M) | Feb 24, 2024 |
NCE-1 date: 2022-02-07
Market Authorisation Date: 07 February, 2018
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
BIKTARVY family patents
5
Japan
4
United States
3
European Union
2
China
2
Australia
1
New Zealand
1
Cyprus
1
San Marino
1
Ecuador
1
RS
1
Uruguay
1
Portugal
1
Canada
1
Brazil
1
India
1
Spain
1
Croatia
1
ME
1
EA
1
Hong Kong
1
Korea, Republic of
1
Lithuania
1
Ukraine
1
Chile
1
Israel
1
Costa Rica
1
Hungary
1
Peru
1
Slovenia
1
Argentina
1
Morocco
1
Mexico
1
Moldova, Republic of
1
Poland
1
Taiwan
1
South Africa
1
Colombia
1
Singapore
1
AP
1
Denmark
21. List of Bortezomib drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(9 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
22. List of Braftovi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
| US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(9 years from now) | |
| US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
| New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 2022-06-27
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...
Dosage: CAPSULE;ORAL
BRAFTOVI family patents
7
United States
2
China
2
Japan
2
European Union
1
New Zealand
1
Cyprus
1
RS
1
Portugal
1
Canada
1
Brazil
1
Spain
1
Malaysia
1
Croatia
1
Jordan
1
Hong Kong
1
EA
1
Korea, Republic of
1
Chile
1
Lithuania
1
Guatemala
1
Ukraine
1
Israel
1
Hungary
1
Peru
1
Slovenia
1
Tunisia
1
Argentina
1
Morocco
1
Australia
1
Philippines
1
Mexico
1
Taiwan
1
South Africa
1
Poland
1
Colombia
1
Singapore
1
Denmark
23. List of Brenzavvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 2027-01-20
Market Authorisation Date: 20 January, 2023
Treatment: NA
Dosage: TABLET;ORAL
24. List of Bunavail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
25. List of Cabometyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
| New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
26. List of Caldolor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(8 years from now) | |
| US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Nov 19, 2024 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis...
Dosage: SOLUTION;INTRAVENOUS
27. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 2021-10-31
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with prev...
Dosage: TABLET;ORAL
CALQUENCE family patents
8
United States
6
Japan
5
European Union
4
Australia
3
Lithuania
3
Israel
3
Hungary
2
New Zealand
2
RS
2
China
2
Portugal
2
Spain
2
Croatia
2
EA
2
Korea, Republic of
2
Slovenia
2
Poland
2
Denmark
1
Cyprus
1
Ecuador
1
Turkey
1
Canada
1
Brazil
1
India
1
Dominican Republic
1
Netherlands
1
Norway
1
Malaysia
1
Chile
1
ME
1
Ukraine
1
Guatemala
1
Costa Rica
1
Peru
1
Tunisia
1
Morocco
1
Philippines
1
Mexico
1
Nicaragua
1
Colombia
1
Singapore
28. List of Calquence drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(9 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB ingredient
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult p...
Dosage: CAPSULE;ORAL
CALQUENCE family patents
8
United States
6
Japan
5
European Union
4
Australia
3
Lithuania
3
Israel
3
Hungary
2
New Zealand
2
RS
2
China
2
Portugal
2
Spain
2
Croatia
2
EA
2
Korea, Republic of
2
Slovenia
2
Poland
2
Denmark
1
Cyprus
1
Ecuador
1
Turkey
1
Canada
1
Brazil
1
India
1
Dominican Republic
1
Netherlands
1
Norway
1
Malaysia
1
Chile
1
ME
1
Ukraine
1
Guatemala
1
Costa Rica
1
Peru
1
Tunisia
1
Morocco
1
Philippines
1
Mexico
1
Nicaragua
1
Colombia
1
Singapore
29. List of Caspofungin Acetate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(9 years from now) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
30. List of Cetylev drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427421 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
| US8747894 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
| US9561204 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(8 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 29 January, 2016
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: TABLET, EFFERVESCENT;ORAL
31. List of Cometriq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) | |
| US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) | |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 29 November, 2012
Treatment: NA
Dosage: CAPSULE;ORAL
32. List of Contrave drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(8 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
33. List of Copiktra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(8 years from now) | |
| US11312718 | SECURA | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
Jan, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 2022-09-24
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
34. List of Cotempla Xr-odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089496 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
| US9072680 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
35. List of Cycloset drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4...
Dosage: TABLET;ORAL
36. List of Daybue drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 10, 2030 |
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2028 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 2027-03-11
Market Authorisation Date: 10 March, 2023
Treatment: Treatment of rett syndrome or a symptom thereof
Dosage: SOLUTION;ORAL